Business Context and Reporting Period
Company: American Technology Corporation (Note: Input metadata referenced "Genasys Inc.", but the filing text identifies the registrant as American Technology Corporation).
Reporting Period: Quarterly period ended March 31, 2001 (Six months ended March 31, 2001).
Business Overview: The Company designs, develops, and commercializes sound, acoustics, and other technologies (including HyperSonic Sound, Stratified Field, NeoPlanar, and PureBass) and sells portable consumer products. The strategy focuses on commercializing technologies through OEM licensing or contract supply agreements.
Key Financial Metrics
| Metric | Six Months Ended Mar 31, 2001 | Six Months Ended Mar 31, 2000 |
|---|---|---|
| Total Revenues | $533,056 | $801,180 |
| Gross Profit | $165,083 (31% margin) | $189,916 (24% margin) |
| Net Loss | $(2,472,952) | $(913,879) |
| Net Loss Available to Common Stockholders | $(2,536,367) | $(3,505,886) |
| Cash and Cash Equivalents (End of Period) | $2,331,936 | $7,186,255 |
| Working Capital | $2,524,976 | $4,794,743 |
| Net Cash Used in Operating Activities | $(2,147,987) | $(1,529,974) |
| Net Cash Used in Investing Activities | $(315,692) | $737,428 |
| Net Cash Provided by Financing Activities | $150,000 | $7,388,565 |
Debt: The Company has no long-term indebtedness. A $40,000 promissory note receivable was issued to an officer in March 2001.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 33% to $533,056 from $801,180. Product sales dropped 60% to $294,750, primarily due to the absence of a one-time seasonal consumer product order in the prior year. Conversely, contract and license revenue increased significantly to $238,306 (from $55,772) due to the sale of patented technology.
- Operating Expenses: Research and development (R&D) expenses increased 79% to $1,595,414, driven by development of HSS evaluation units, PMT technology, and increased engineering personnel. Selling, general, and administrative (SG&A) expenses decreased 6% to $1,148,913 due to reduced personnel and travel costs.
- Liquidity: Cash decreased by approximately $2.3 million during the six-month period. Working capital declined from $4.79 million to $2.52 million.
- Profitability: While the Company remains unprofitable with a net loss of $2.47 million, the gross profit margin improved to 31% from 24% in the prior year, largely due to the high-margin sale of patented technology.
Guidance, Outlook, and Risks
- Funding Requirements: Management estimates a minimum additional funding requirement of approximately $2 million for the next twelve months. The Company does not have sufficient funds to operate for the next 12 months without additional capital from sales, licensing, or equity financing.
- Strategic Developments:
- Entered a Letter of Intent with Harman International Industries for NeoPlanar technology rights (April 2001).
- Exclusive marketing agreement with Americhip Inc. for HSS technology.
- Licensing partnership with SoundIdeas for HSS technology.
- Risks:
- Liquidity Risk: Inability to secure funding could force the curtailment of operations.
- Commercialization Risk: Future success depends on the market acceptance of sound technologies, which have not yet generated significant revenue.
- Customer Concentration: Sales are concentrated with a few customers and subject to seasonal variability.
- Supply Chain: Reliance on outside manufacturers for portable consumer products.
- Unusual Items: The net loss includes non-cash accretion on Series B and Series C Preferred Stock ($63,415 for the six months). The prior year included a significant gain on the sale of investment securities ($988,112) which is not present in the current period.
Investor Verification Checklist
- Cash Runway: Verify the Company's ability to raise the estimated $2 million required for the next 12 months.
- Harman Agreement: Confirm if the Letter of Intent with Harman International Industries has been finalized into a definitive agreement.
- Revenue Sustainability: Assess whether the $200,000 revenue from the sale of patented technology is a recurring event or a one-time transaction.
- R&D Efficiency: Monitor the conversion of increased R&D spending ($1.6M) into commercializable products or licensing deals.
- Preferred Stock Accretion: Review the impact of Series B and C Preferred Stock accretion on future net loss available to common stockholders.